Table 5 Summary of physical symptom efficacy measures
From: Duloxetine in the treatment of major depressive disorder: an open-label study
| Â | Baseline, mean (SD) | Endpoint, mean (SD) | p-valuea |
|---|---|---|---|
VAS pain severity | Â | Â | Â |
   Overall (n = 504) | 33.8 (26.6) | 21.3 (25.6) | T = -10.5, df = 503 p < .001, |
   Headache (n = 504) | 27.6 (27.8) | 15.3 (22.4) | T = -9.4, df = 503, p < .001 |
   Back pain (n = 504) | 28.7 (29.3) | 15.8 (23.3) | T = -10.7, df = 503, p < .001 |
   Shoulder pain (n = 501) | 23.1 (28.9) | 14.1 (23.2) | T = -7.7, df = 500, p < .001 |
   Interference with daily activities (n = 501) | 28.2 (28.2) | 17.3 (25.3) | T = -8.8, df = 500, p < .001 |
   Time in pain while awake (n = 500) | 38.3 (32.2) | 23.3 (28.6) | T = -10.3, df = 499, p < .001 |
Symptom Questionnaire, Somatic Subscale (n = 492) | 12.4 (5.3) | 7.6 (5.1) | T = -19.5, df = 491, p < .001 |
Symptom Questionnaire, Somatic Subscale pain items (n = 504) | 4.9 (2.4) | 3.5 (2.6) | T = -11.9, df = 503, p < .001 |